Management of cancer therapy-induced oral mucositis

Dermatol Ther. 2011 Jul-Aug;24(4):424-31. doi: 10.1111/j.1529-8019.2011.01434.x.

Abstract

The oral mucosa is a common site for collateral damage of cancer therapies, including radiation, cytotoxic medication, and newer targeted therapies. Ulcerative oral mucositis is typically painful and affects oral functions including speech, and oral intake of food and medications, thus impacting the quality of life. Denuded epithelium may also provide access of oral microbial flora to the deeper tissues and the circulation. Prevention of oral mucositis is an ongoing quest currently with relatively few answers. In this chapter, the present authors discuss the evidence and current practice for prophylaxis and management of this treatment side effect in cancer patients.

Publication types

  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / adverse effects*
  • Antineoplastic Agents / therapeutic use
  • Drug Delivery Systems
  • Humans
  • Neoplasms / therapy*
  • Quality of Life
  • Radiation Injuries / pathology
  • Radiation Injuries / prevention & control
  • Stomatitis / etiology*
  • Stomatitis / pathology
  • Stomatitis / prevention & control

Substances

  • Antineoplastic Agents